Claims
- 1. A viable, physiologically active and biocompatible cellular or tissue implant having (a) a total volume greater than 10 cubic millimeters, (b) a tissue or cell content of at least 10% by volume, and (c) dimensions permitting sufficient oxygen diffusion to sustain cell or tissue viability when the implant is implanted into a vascularized site in a patient.
- 2. The implant of claim 1, wherein said total volume is at least 100 cubic millimeters.
- 3. The implant of claim 1, wherein said total volume is at least 500 cubic millimeters.
- 4. The implant of claim 1, wherein said tissue or cell content is at least 20% by volume.
- 5. The implant of claim 2, wherein said tissue or cell content is at least 35% by volume.
- 6. The implant of claim 1, wherein the implant has a thin sheet configuration.
- 7. The implant of claim 1, wherein the implant has a thickness of less than 400 .mu.m.
- 8. The implant of claim 1, wherein the implant is retrievable.
- 9. The implant of claim 1, wherein the implant comprises (a) a core of living tissue and a first gelled alginate, surrounded by (b) one or more layers of a second gelled alginate, which may be the same as or different from said first gelled alginate.
- 10. The implant of claim 9, wherein said core further comprises one or more trophic factors or nurse cells.
- 11. The implant of claim 9, wherein said core further comprises a substrate material.
- 12. The implant of claim 9, where said core further comprises an antioxidant material.
- 13. The implant of claim 9, wherein said living tissue comprises islets of Langerhans.
- 14. A method of treating or preventing a disease which can be treated or prevented with an active agent secreted by a cell or tissue, comprising implanting the implant of claim 1 in a patient in need thereof.
- 15. A method of treating or preventing a disease which can be treated or prevented by catabolism of a disease-causing agent or substance in a cell or tissue, comprising implanting the implant of claim 1 in a patient in need thereof.
- 16. The method of claim 14, wherein said disease is diabetes.
- 17. The implant of claim 9, wherein said core further comprises trophic factors and nurse cells.
Parent Case Info
This application is a division of 08/542,506 now U.S. Pat. No. 5,855,613 filed Oct. 13, 1995.
US Referenced Citations (33)
Foreign Referenced Citations (3)
Number |
Date |
Country |
42 29 526 A1 |
Mar 1994 |
DEX |
WO 9324077 |
Dec 1993 |
WOX |
9518583 |
Jul 1995 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Vox Sanquinis, vol. 68: 82-89, Feb. 1995, Boomgaard et al., Pooled Platelet Concentration Prepared by the. |
Sambanis et al., Towards the development of a bioartificial pancreas: immunoisolation and NMR monitoring of mouse insulinomas, Cytotechnology (1994) 15(1-3): 351-363. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
542506 |
Oct 1995 |
|